Erasca
ERASNASDAQRAS pathway-focused precision oncology platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
SEACRAFT-2: Naporafenib + trametinib in NRAS-mutant cutaneous melanoma — primary completion
2028-04
Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Naporafenib | NRAS-mutant melanoma | Phase 3 | Not disclosed | ▼ |
| ERAS-007 | RAS/MAPK-driven solid tumors | Phase 1 | Not disclosed | ▼ |
| ERAS-601 | solid tumors | Phase 1 | Not disclosed | ▼ |
Analysis
Comparable companies
Sponsored
Get premium ERAS analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you